Human medicines European public assessment report (EPAR): Heplisav B, hepatitis B surface antigen, Hepatitis B, Date of authorisation: 18/02/2021, Revision: 3, Status: Authorised
Heplisav B is a vaccine for preventing hepatitis B virus infection in adults. It is also likely to prevent infection with the hepatitis D virus as this virus is only present in people with hepatitis B infection.
Heplisav B is used in accordance with official recommendations. It contains a protein from the hepatitis B virus.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
